Practice-Changing Advances in Systemic Therapies Shaping the Landscape of Lung Cancer in 2025.

Abstract

With the rapid advancement of molecular profiling and precision therapeutics, targeted and immunotherapeutic strategies have irrevocably reshaped the pharmacological management for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Overall mortality from lung cancer has continued its downward trend over the past decade, and this decline has accelerated, largely driven by advances in early detection and curative-intent surgeries. In parallel, the systemic therapies have undergone a dramatic evolution with the integration of, for example, antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs). The year 2025 marks a period of significant progress in lung cancer treatment, characterized by groundbreaking therapeutic successes across all disease stages and subtypes. This comprehensive review synthesizes pivotal evidence presented at key oncology forums in 2025 to delineate the substantially evolved clinical landscape.